Global pharma major Lupin Limited (Lupin) announced the launch of Liraglutide Injection, 18 mg/3 mL (6 mg/mL) Single-Patient-Use Prefilled Pen, in the United States.

Liraglutide Injection, 18 mg/3 mL (6 mg/mL) Single-Patient-Use Prefilled Pen is bioequivalent to Victoza Injection, 18 mg/3 mL (6 mg/mL) of Novo Nordisk. It is indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older, with type 2 diabetes mellitus.

Liraglutide Injection, 18 mg/3 mL (6 mg/mL) Single-Patient-Use Prefilled Pen (RLD Victoza) had an estimated annual sale of US$ 350 million in the U.S. (IQVIA MAT Aug 2025).

Spiro Gavaris, President - U.S. Generics, Lupin, said, "We are pleased to launch Liraglutide Injection in the U.S. This marks a significant milestone in enhancing our portfolio of complex injectables and highlights our continued commitment to making essential therapies more accessible for patients."